We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal (CAH) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
Analysts on Wall Street project that Cardinal Health (CAH - Free Report) will announce quarterly earnings of $2.21 per share in its forthcoming report, representing an increase of 17.6% year over year. Revenues are projected to reach $59.05 billion, increasing 13% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Cardinal metrics that are commonly tracked and projected by analysts on Wall Street.
According to the collective judgment of analysts, 'Revenue- Pharmaceutical and Specialty Solutions' should come in at $54.30 billion. The estimate indicates a year-over-year change of +13.2%.
The consensus estimate for 'Revenue- Other' stands at $1.56 billion. The estimate suggests a change of +31.2% year over year.
Analysts predict that the 'Revenue- Medical Products and Distribution' will reach $3.21 billion. The estimate indicates a year-over-year change of +2.9%.
Analysts expect 'Segment profit- Pharmaceutical and Specialty Solutions' to come in at $596.71 million. Compared to the current estimate, the company reported $530.00 million in the same quarter of the previous year.
It is projected by analysts that the 'Segment profit- Other' will reach $139.45 million. Compared to the current estimate, the company reported $104.00 million in the same quarter of the previous year.
Analysts' assessment points toward 'Segment profit- Global Medical Products and Distribution' reaching $23.82 million. The estimate compares to the year-ago value of $8.00 million.
Over the past month, shares of Cardinal have returned +6% versus the Zacks S&P 500 composite's +3.6% change. Currently, CAH carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cardinal (CAH) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Analysts on Wall Street project that Cardinal Health (CAH - Free Report) will announce quarterly earnings of $2.21 per share in its forthcoming report, representing an increase of 17.6% year over year. Revenues are projected to reach $59.05 billion, increasing 13% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some Cardinal metrics that are commonly tracked and projected by analysts on Wall Street.
According to the collective judgment of analysts, 'Revenue- Pharmaceutical and Specialty Solutions' should come in at $54.30 billion. The estimate indicates a year-over-year change of +13.2%.
The consensus estimate for 'Revenue- Other' stands at $1.56 billion. The estimate suggests a change of +31.2% year over year.
Analysts predict that the 'Revenue- Medical Products and Distribution' will reach $3.21 billion. The estimate indicates a year-over-year change of +2.9%.
Analysts expect 'Segment profit- Pharmaceutical and Specialty Solutions' to come in at $596.71 million. Compared to the current estimate, the company reported $530.00 million in the same quarter of the previous year.
It is projected by analysts that the 'Segment profit- Other' will reach $139.45 million. Compared to the current estimate, the company reported $104.00 million in the same quarter of the previous year.
Analysts' assessment points toward 'Segment profit- Global Medical Products and Distribution' reaching $23.82 million. The estimate compares to the year-ago value of $8.00 million.
View all Key Company Metrics for Cardinal here>>>Over the past month, shares of Cardinal have returned +6% versus the Zacks S&P 500 composite's +3.6% change. Currently, CAH carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .